Cargando…

Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis

Detalles Bibliográficos
Autores principales:	van Leeuwen, Jolijn R, Popov, Tamara, Obergfell, Achim, Rabelink, Ton J, Teng, Y K Onno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884459/ https://www.ncbi.nlm.nih.gov/pubmed/36721867 http://dx.doi.org/10.2147/BTT.S394843

Ejemplares similares

Response to “Tailored Use of Avacopan in a Case With Refractory Antineutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis and Concominant Complement System Activation”
por: van Leeuwen, Jolijn R., et al.
Publicado: (2022)

Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: van Leeuwen, Jolijn R., et al.
Publicado: (2021)

Journal Club Review of “Avacopan for the Treatment of ANCA‐Associated Vasculitis”
por: Soulsby, William Daniel
Publicado: (2022)

The impact of reclassification by the 2022 ACR/EULAR classification criteria on risk factors for relapse in patients with ANCA-associated vasculitis
por: van Leeuwen, Jolijn R, et al.
Publicado: (2023)

Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
por: Aqeel, Faten, et al.
Publicado: (2023)

Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan
por: Alvarez, Luis, et al.
Publicado: (2023)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

Avacopan improves patient perspective on steroid-related toxicity effects in a case with ANCA-associated vasculitis
por: Korsten, Peter, et al.
Publicado: (2023)

ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial
por: Dirikgil, Ebru, et al.
Publicado: (2022)

Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patients
por: Dirikgil, Ebru, et al.
Publicado: (2022)

Avacopan as First-Line Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Steroid-Sparing Option
por: Gabilan, Charlotte, et al.
Publicado: (2022)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Merkel, Peter A., et al.
Publicado: (2020)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-associated vasculitis of the appendix
por: Leaver, Phillip J, et al.
Publicado: (2019)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

Avacopan in Patients With Rapidly Progressive Glomerulonephritis Requiring Dialysis
por: Cortazar, Frank B., et al.
Publicado: (2023)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Wallace, Zachary S., et al.
Publicado: (2019)

Tailored Use of Avacopan in a Case With Refractory Antineutrophil Cytoplasmic Antibody-Associated Renal Vasculitis and Concominant Complement System Activation
por: Hakroush, Samy, et al.
Publicado: (2022)

Progress in treatment of ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2012)

Animal Models of ANCA Associated Vasculitis
por: Shochet, Lani, et al.
Publicado: (2020)

Eye involvement in ANCA positive vasculitis
por: Macarie, Sorin Simion, et al.
Publicado: (2020)

Mechanisms of thrombosis in ANCA-associated vasculitis
por: Misra, Durga Prasanna, et al.
Publicado: (2021)

Granulomatous Inflammation in ANCA-Associated Vasculitis
por: Müller, Antje, et al.
Publicado: (2021)

Complement Inhibition in ANCA-Associated Vasculitis
por: Tesar, Vladimir, et al.
Publicado: (2022)

The involvement of NETs in ANCA-associated vasculitis
por: Shiratori-Aso, Satoka, et al.
Publicado: (2023)

Avacopan/methylprednisolone/prednisone: Various toxicities: 8 case reports
Publicado: (2022)

Circulating autoreactive proteinase 3(+) B cells and tolerance checkpoints in ANCA-associated vasculitis
por: Berti, Alvise, et al.
Publicado: (2021)

Pathophysiology of ANCA-Associated Small Vessel Vasculitis
por: Kallenberg, Cees G. M.
Publicado: (2010)

Ocular disease in patients with ANCA-positive vasculitis
por: Watkins, Angela S., et al.
Publicado: (2009)

Levamisole-Induced ANCA Vasculitis and Cutaneous Necrosis
por: Tichauer, Matthew, et al.
Publicado: (2014)

Familial clusters of ANCA small-vessel vasculitis
por: Gomes, Ana Marta, et al.
Publicado: (2009)

Interstitial Lung Disease with ANCA-associated Vasculitis
por: Katsumata, Yasuhiro, et al.
Publicado: (2015)

Neutrophil Extracellular Traps in ANCA-Associated Vasculitis
por: Söderberg, Daniel, et al.
Publicado: (2016)

ANCA-associated vasculitis in childhood: recent advances
por: Calatroni, Marta, et al.
Publicado: (2017)

FIBROTIC PROTEASE 3 ANCA-ASSOCIATED VASCULITIS
por: Megri, Mohammed, et al.
Publicado: (2020)

Therapy of ocular complications in ANCA+ associated vasculitis
por: Macarie, Sorin Simion, et al.
Publicado: (2021)

ANCA-associated vasculitis after COVID-19
por: Izci Duran, Tugba, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f9k3l4ecd42cs8ub4r9ca5fvef